This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Integra (IART) Rises 5% on Robust Preliminary Q4 Results
by Zacks Equity Research
Integra's (IART) total Q4 revenues are likely to be at the upper end of its prior guided range.
Boston Scientific Gains on Impressive Preliminary Q4 Results
by Zacks Equity Research
Boston Scientific's (BSX) solid top line is expected to be backed by growth across all segments and geographical regions in Q4.
ResMed Announces Complete Mobi Launch in US Markets for COPD
by Zacks Equity Research
ResMed (RMD) progresses with efforts to boost Respiratory Care suite.
QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales
by Zacks Equity Research
QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.
Hologic Stock Rides on Impressive Preliminary Q1 Result
by Zacks Equity Research
Hologic's (HOLX) strong top line is primarily expected on the back of balanced growth across a majority of the company's segments in Q1.
ResMed Closes Propeller Health Buyout, Boosts COPD Suite
by Zacks Equity Research
ResMed (RMD) expects to boost the Respiratory Care suite with the recently-completed Propeller Health buyout.
Cardiovascular Systems Expands Portfolio Amid Stiff Rivalry
by Zacks Equity Research
Cardiovascular Systems (CSII) continues to expand its portfolio to widen the company's reach. However, Cardiovascular Systems operating in a highly competitive environment is a concern.
Neogen's Canadian Lab Buyout to Boost Genomics Business
by Zacks Equity Research
Neogen (NEOG) continues to adopt initiatives to boost the genomics business.
LabCorp Rides on Covance Business Amid Reimbursement Woes
by Zacks Equity Research
Within Covance Drug Development business, LabCorp (LH) aims at reaping huge profits via expanded solutions and better operational skills.
Omnicell (OMCL) Rides on Innovation Despite Cost Concerns
by Zacks Equity Research
Omnicell (OMCL) steadily sees a solid uptake of Omnicell XT. It also strikes various deals for the XR2 and IVX Workflow products.
LabCorp, GENFIT Tie-Up to Develop Test for NASH, Widen Suite
by Zacks Equity Research
LabCorp (LH) continues to strengthen foothold in the diagnostics space through organic and inorganic means.
Here's Why You Should Add CVS Health to Your Portfolio Now
by Zacks Equity Research
CVS Health (CVS) is optimistic about synergies from Aetna deal which will help create a robust platform to serve individuals better.
Solid Global Business Aids NuVasive Amid Pricing Pressure
by Zacks Equity Research
Per NuVasive (NUVA), the international region holds significant growth opportunity. However, pricing pressure is a major headwind.
Cardiovascular Systems Gets Approvals in Japan, Widens Suite
by Zacks Equity Research
Cardiovascular Systems (CSII) continues to expand product portfolio to enhance market reach and versatility.
Has the Trade Debacle Ended for US MedTech Space? 3 Picks
by Sreyoshi Mukherjee
As the trade war fears slowly dissipate, let's take a look at three profitable U.S. MedTech picks.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) is developing and acquiring new business lines that will complement its existing home care and hospice business.
Walgreens Counts on International Progress, Strategic Deals
by Zacks Equity Research
We are upbeat about Walgreens' (WBA) recent pact with Alphabet???s life sciences and healthcare segment, Verily, to coordinate on multiple projects with respect to chronic ailments.
Cardiovascular Systems Treats First Patient With Teleport
by Zacks Equity Research
Cardiovascular Systems (CSII) expands product portfolio to enhance market reach and versatility.
Here's Why You Should Invest in Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Hill-Rom's (HRC) M&A pipeline continues to be strong.
Boston Scientific (BSX) to Buy Residual Shares of Millipede
by Zacks Equity Research
Boston Scientific's (BSX) buyout of the leftover stake in Millipede will integrate the latter's IRIS Transcatheter Annuloplasty Ring System in the Structural Heart portfolio of the former.
Zimmer Biomet (ZBH) Thrives on New Projects, APAC Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) is performing well on the back of its two largest commercial projects, namely the Persona Revision system and the Rosa robotics knee application.
Medtronic's Growth Across All Lines Aid, Rising Costs Ail
by Zacks Equity Research
Of late, Medtronic (MDT) succeeds in delivering solid top-line growth at CER, backed by balanced growth across major business operation.
Myriad Genetics Posts Positive Adjusted Vectra Test Data
by Zacks Equity Research
The key finding of Myriad Genetics' (MYGN) study proves that the adjusted Vectra score beats all traditional measures of disease activity to predict radiographic progression in RA patients.
SYK vs. SRDX: Which MedTech Stock Should Investors Pick?
by Zacks Equity Research
Surmodics (SRDX) scores higher than Stryker (SYK) in terms of current-year revenue projections and fundamentals.
Here's Why You Should Buy Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
As a result of continued efforts to streamline operations, Integer Holdings (ITGR) has been registering strong profits over the last couple of quarters.